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MYD88	 mutations,	 L265P	 in	 three	 and	 P258L	 in	 one,	 were	 shared	 by	 four	 pairs.	
Unique	somatic	mutations	were	observed	in	all	five	intra-	CNS	tumors	and	in	four	out	
of	 five	extra-	CNS	tumors.	Remarkably,	 IgH	 clones	 in	 the	 intra-	and	the	extra-	CNS	
tumors	in	two	pairs	were	distinct	from	each	other,	whereas	one	pair	of	tumors	shared	
identical	monoclonal	 IgH	 rearrangement.	 In	a	cohort	of	23	PCNSL	patients,	L265P	
MYD88	 mutations	 were	 examined	 in	 tumor-	free	 BM	mononuclear	 cells	 (MNC)	 in	
which	 the	PCNSL	 tumors	had	L265P	MYD88	mutations.	L265P	MYD88	mutations	
were	detected	by	a	droplet	digital	PCR	method	in	nine	out	of	23	bone	marrow	mono-
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MYD88,	which	results	 in	 the	conversion	from	 leucine	to	proline	at	
the	265th	position	(L265P	MYD88	mutation),	has	a	very	high	preva-
lence	in	patients	with	PCNSL	(38%-	85.4%).2-5
A	 previous	 report	 showed	 that	 the	 L265P	 MYD88	 mutation,	
but	not	other	mutations,	 found	 in	PCNSL	 tumors	was	detected	 in	
peripheral	blood	mononuclear	cells	(PBMNC).3	This	may	imply	that	
the	L265P	MYD88	mutation	may	occur	at	the	extra-	central	nervous	





cursor	 cells	 (CPC)	 for	 the	 primary	 and	 relapsed	 tumors	 in	 other	
types	of	 lymphoma	such	as	follicular	 lymphomas	(FL)	and	mantle	
cell	 lymphomas	 (MCL).6,7	Primary	and	relapsed	tumors	of	FL	and	
MCL	may	 arise	 through	 a	divergent	 evolution	pattern	 from	CPC	
by	acquiring	mutations	specific	 to	either	primary	or	 relapsed	tu-
mors.6,7	 PCNSL	 recurs	 within	 the	 CNS	 in	 most	 relapsed	 cases,	




ing	 the	 initiating	events	by	examining	MYD88	mutations	 in	bone	
marrow	mononuclear	cells	(BMMNC).
2  | MATERIAL S AND METHODS
2.1 | Targeted deep sequencing by Ion Torrent PGM
Targeted	 deep	 sequencing	 (TDS)	 was	 carried	 out	 in	 five	 paired	
primary	 intra-	CNS	 and	 relapsed	 extra-	CNS	 tumors	 and	 BMMNC	











carrying	 out	 alignment	 with	 the	 hg19	 human	 reference	 genome	
and	variant	calling	was	done	with	Variant	Caller	5.2	(Thermo	Fisher	
Scientific).	 Single	 nucleotide	 variants	 or	 insertions/deletions	 with	
frequencies	 of	 3%	or	more	were	 considered	 candidate	mutations.	
These	mutations	were	validated	by	genomic	PCR	followed	by	Sanger	
sequencing.	The	primers	are	listed	in	Table	S3.
2.2 | Polymerase chain reaction detection of 
complementarity- determining region 3 region of Ig 
heavy chain genes










first	 PCR	 (35	 cycles)	 contained	 100	ng	DNA	 and	 the	 second	 PCR	
(20	cycles)	contained	1	μL	of	 the	undiluted	first	PCR	product.	The	














international	 ImMunoGeneTics	 information	system	 (IMGT)	 (http://
www.imgt.org).10
3  | RESULTS


























3.2 | Recurrently mutated genes in PCNSL patients
Targeted	deep	sequencing	was	carried	out	for	39	genes	in	five	tumor	
pairs	 using	 the	 Lymphopanel8	 and	 our	 in-	house	 PCNSL	 panel.4 
Mean	coverages	 in	each	panel	were	1593	×	(range,	370-	3099)	and	
1563	×	(range,	 1084-	1990),	 respectively.	 In	 primary	 intra-	CNS	 tu-
mors,	 61	 probable	 somatic	mutations	were	 identified	 including	 53	
nonsilent	 single	 nucleotide	 variants	 (SNV),	 seven	 deletions,	 and	
one	 insertion.	Recurrent	gene	mutations	were	found	 in	these	such	






(3/5),	PIM1	 (4/5),	KMT2D	 (3/5),	 and	PRDM1	 (3/5)	were	 recurrently	
mutated	 (Figure	1;	 Table	 S8).	 An	 aberrant	 somatic	 hypermutation	
(aSHM)	indicator	value	was	calculated	according	to	the	algorithm	of	
Khodabakhshi	 et	al.12	 The	 value	was	 lower	 than	 0.1,	 showing	 that	
PIM1	mutations	were	associated	with	aSHM	(Data	S1,	Table	S9).12
3.3 | Landscape of somatic mutations in 
primary intra- and relapsed extra- CNS tumors of 
PCNSL patients
We	found	shared	mutations	 in	all	 five	paired	tumors	and	unique	
mutations	 in	 all	 five	 intra-	CNS	 tumors	 and	 in	 four	 out	 of	 five	
extra-	CNS	 tumors	 (Figure	2).	 In	 total,	 16	mutations	 in	 11	 genes	
were	found	to	be	shared	(Figures	2	and	3;	Table	S8).	MYD88	(4/5)	
mutations,	L265P	 in	 three	and	P258L	 in	one,	were	 the	most	 re-
currently	shared	mutations.	CD79B	(3/5),	KMT2D	(3/5),	and	PIM1 
(2/5)	 mutations	 also	 emerged	 as	 recurrently	 shared	 mutations,	
among	which	Y196	CD79B	 (3/5),	and	Q2951R	KMT2D	 (2/5)	were	
identified	 as	 hotspot	 mutations	 (Figure	1,	 Table	 S8).	 Forty-	five	





3.4 | Divergent evolution of primary intra- and 
relapsed extra- CNS tumors from a CPC
These	distribution	patterns	of	shared	and	separated	mutations	strongly	
indicated	the	presence	of	CPC	that	precedes	the	development	of	pri-
mary	 intra-	CNS	 tumors.	 To	 seek	 the	 localization	 of	 the	 CPC	 in	 the	 
B-	lineage	cell	differentiation	map,	IgH	rearrangement	status	of	paired	
tumors	was	examined	in	paired	tumors	of	patients	T1,	T5,	and	TP39	






















and	 intra-	CNS	 tumors	 of	 patients	 T5	 and	 TP39	 could	 not	 be	 deter-
mined	by	direct	sequencing.	Then,	the	PCR	products	were	cloned	into	








F IGURE  4  IgH	rearrangement	status	of	paired	tumors	in	patient	T1.	(A)	Photographs	of	PCR	gels	and	(B)	the	electropherogram	of	direct	
sequencing	show	the	IgH	rearrangement	status	of	paired	tumors	in	patient	T1.	CNS,	central	nervous	system
























intra-	CNS	 tumor,	 those	 with	 VH4-	4*07/DH5-	24*01/JH4*01	 in	 16/17	
[94%]	 and	 in	 TP39	 extra-	CNS	 tumor,	 those	 with	 VH3-	21*01/DH6-	
19*01/JH4*01	 in	15/18	 [83%]	 (Table	S10).	Almost	all	VH	were	highly	
mutated	(T5	intra-	CNS	tumor,	17/18;	T5	extra-	CNS	tumor,	14/17;	TP39	
intra-	CNS	 tumor,	 16/17;	 TP39	 extra-	CNS	 tumor,	 18/18)	 presumably	
because	of	ongoing	hypermutation13–16	(Table	S10,	Figure	S3).
These	analyses	imply	that	the	CPC	is	mapped	at	distinct	positions	
in	 B-	lineage	 differentiation;	 the	 position	 after	 IgH	 rearrangement	
and	even	after	hypermutation	at	the	variable	region	was	suggested	
in	 T1,	whereas	 emergence	 of	 CPC	 before	 IgH	 rearrangement	was	
suggested	in	T5	and	TP39.
3.5 | Detection of L265P MYD88 mutations in 
BMMNC or PBMNC with droplet digital PCR
To	further	characterize	the	initiation	of	PCNSL	that	is	theorized	to	
precede	the	emergence	of	CPC,	we	analyzed	PBMNC	of	T1	collected	






MYD88	mutations	were	 identified	 in	PBMNC	 (T1)	 and	 in	nine	out	




This	 is	 the	 first	 multidimensional	 study	 of	 mutational	 dynam-
ics	 comparing	mutational	 profiles	 between	 intra-	CNS	 tumors	 and	
extra-	CNS	 tumors.	 In	 our	 study,	 all	 the	 five	 paired	 tumors	 shared	
multiple	mutations.	Unique	somatic	mutations	were	observed	in	all	
the	 five	 intra-	CNS	 tumors	 and	 four	 out	 of	 five	 extra-	CNS	 tumors	
(Table	S8,	Figure	S2).	Among	the	somatic	mutations	specific	to	intra-	
CNS	tumors,	TBL1XR1	mutation	was	reported	to	be	more	prevalent	
in	PCNSL	 than	 in	DLBCL	not	otherwise	 specified	 (NOS).17	 In	 con-
trast,	a	SOCS1	mutation	was	detected	in	the	tumor	of	subcutaneous	
tissue	 in	TP44	(Table	S4).	SOCS1	mutations	are	known	to	be	more	
prevalent	 in	primary	cutaneous	diffuse	 large	B-	cell	 lymphoma,	 leg	
type	compared	 to	DLBCL	NOS.18	 Therefore,	 somatic	mutations	 in	
these	genes	may	bias	the	location	of	tumors.	These	results	suggest	
that	 the	 paired	 tumors	 originate	 from	divergent	 evolution	 of	CPC	
through	accumulation	of	distinct	mutations.
Recent	 studies	 have	 proposed	 that	 primary	 and	 relapsed	 tu-
mors	 in	 several	hematological	 cancers	may	arise	 from	CPC.6,7,18-20 
Previously,	 it	was	 reported	 that	 the	 dominant	 clones	were	 identi-
cal	 in	paired	 tumors	of	primary	and	 relapsed	MCL	and	FL	accord-
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VDJ	 rearrangement	 (Figure	6).6,7	 In	 contrast,	 in	 a	 part	 of	 Richter	
syndrome,	 distinct	 IgH	 clones	were	 observed	 between	 aggressive	
lymphomas	and	primary	chronic	lymphocytic	leukemia	(CLL)	tumors	










PCNSL	patients.21	These	 results	suggest	 that	divergence	 from	the	
CPC	could	occur	after	the	point	of	IgH	rearrangement	in	all	of	these	
patients,	 although	 hypermutations	 occurred	 independently	 in	 IgH 







It	 has	 been	 suggested	 that,	 in	 FL	 and	MCL,	 the	 initial	 genetic	
events	may	occur	in	pre-	B	stage	of	differentiation	during	the	recom-
bination	 of	 the	VDJ	 segments	 in	 the	BM	because	 the	 tumor	 cells	
harbor IgH	fusions	with	other	genes:	IgH/BCL2	in	FL	and	IgH/CCND1 
in	MCL.	 In	several	types	of	 lymphomas,	the	 initiating	events	could	
be	 tracked	 back	 even	 to	 hematopoietic	 stem/progenitor	 cells	 up-
stream	of	the	lineage	commitment	towards	either	B	cells	or	T	cells:	
NOTCH1 and SF3B1	mutations	in	CLL,22 BRAF	mutations	in	hairy	cell	
leukemia23 and TET2/DNMT3A	 mutations	 in	 angioimmunoblastic	
T-	cell	 lymphomas.24-26	 Frequent	 detection	 of	 L265P	 MYD88 mu-





of	 lymphoma	 cells	 in	 the	BM	was	 not	 completely	 excluded	 in	 our	
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